Simvastatin antagonizes tumor necrosis factor-α ihibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway

Journal of Endocrinology

Volumn 196, Issue 3, 2008, Pages 601-613

  Yamashita, Misuzu ^a   Otsuka, Fumio ^a   Mukai, Tomoyuki ^b   Otani, Hiroyuki ^a   Inagaki, Kenichi ^a   Miyoshi, Tomoko ^a   Goto, Junko ^a   Yamamura, Masahiro ^b   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; COMPLEMENTARY DNA; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; RAS PROTEIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; SMAD PROTEIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE INJURY; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA MICROARRAY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; INFLAMMATION; LIPOPHILICITY; MOUSE; MYOBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTORS; CELL DIFFERENTIATION; CELL LINE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DRUG INTERACTIONS; GENE EXPRESSION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MAP KINASE SIGNALING SYSTEM; MICE; MYOBLASTS; OSTEOBLASTS; RAS PROTEINS; RHO-ASSOCIATED KINASES; SIMVASTATIN; SMAD PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41149125432     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-07-0532     Document Type: Article

References (63)

1. Auer J, Berent R, Weber T & Eber B 2002 Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Current Medicinal Chemistry 9 1831-1850.
2. Baud V & Karin M 2001 Signal transduction by tumor necrosis factor and its relatives. Trends in Cell Biology 11 372-377.
3. Bauer DC 2003 HMG CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporosis International 14 273-282.
4. Bellosta S, Ferri N, Bernini F, Paoletti R & Corsini A 2000 Non-lipid-related effects of statins. Annals of Medicine 32 164-176.
5. Casey PJ & Seabra MC 1996 Protein prenyltransferases. Journal of Biological Chemistry 271 5289-5292.
6. Celeste AJ, Iannazzi JA, Taylor RC, Hewick RM, Rosen V, Wang EA & Wozney JM 1990 Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. PNAS 87 9843-9847.
7. Chen G & Goeddel DV 2002 TNF-R1 signaling: a beautiful pathway. Science 296 1634-1635.
8. Chen S, Guttridge DC, Tang E, Shi S, Guan K & Wang CY 2001 Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor κB-independent bone morphogenetic protein/Smad signaling. Journal of Biological Chemistry 276 39259-39263.
9. Duey P, Zhang R, Geoffrey V, Ridall AL & Karsenty G 1997 Osf2/Cbfal: a transcriptional activator of osteoblast differentiation. Cell 89 747-754.
10. Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabata M, Miyazono K & Imamura T 1999 Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. Journal of Cell Science 112 3519-3527.
11. Feldmann M & Maini RN 2001 Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annual Review of Immunology 19 163-196.
12. Feldmann M, Brennan FM & Maim RN 1996 Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 14 397-440.
13. Fromigue O, Hay E, Modrowski D, Bouvet S, Jacquel A, Auberger P & Marie PJ 2006 RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death and Diferentiation 13 1845-1856.
14. Frost R-A, Nystrom GJ & Lang CH 2003a Tumor necrosis factor-alpha decreases insulin-like growth factor-I messenger ribonucleic acid expression in C2C12 myoblasts via a Jun N-terminal kinase pathway. Endocrinology 144 1770-1779.
15. Frost RA, Nystrom GJ & Lang CH 2003b Lipopolysaccharide and proinflammatory cytokines stimulate interleukin-6 expression in C2C12 myoblasts: role of the Jun NH2-terminal kinase. American Journal of Physiology, Regulatory, Integrative and Comparative Physiology 285 R1153-R1164.
16. Garrett IR & Mundy GR 2002 The role of statins as potential targets for bone formation. Arthritis Research 4 237-240.
17. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z & Ferrara N 1999 VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nature Medicine 5 623-628.
18. Ghosh-Choudhury N, Mandal CC & Choudhury GG 2007 Statin-induced Ras activation integrates the phosphatidylinositol 3-kinase signal to Akt and MAPK for bone morphogenetic protein-2 expression in osteoblast differentiation. Journal of Biological Chemistry 282 4983-4993.
19. Goad DL, Rubin J, Wang H, Tashjian AH Jr & Patterson C 1996 Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137 2262-2268.
20. Goldstein JL & Brown MS 1990 Regulation of the mevalonate pathway. Nature 343 425-430.
21. Hamelin BA & Targeon J 1998 Hydrophilicity/lipophilicity: relevance for the Pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends in Pharmacological Sciences 19 26-37.
22. Hu H, Sung A, Zhao G, Shi L, Qiu D, Nishimura T & Kao PN 2006 Simvastatin enhances bone morphogenetic protein receptor type II expression. Biochemical and Biophysical Research Communications 339 59-64.
23. Hughes FJ, Collyer J, Stanfield M & Goodman SA 1995 The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology 136 2671-2677.
24. Inagaki K, Otsuka F, Suzuki J, Kano Y, Takeda M, Miyoshi T, Otani H, Mimura Y, Ogura T & Makino H 2006 Involvement of bone morphogenetic protein-6 in differential regulation of aldosterone production by angiotensin II and potassium in human adrenocortical cells. Endocrinology 147 2681-2689.
25. Jadhav SB & Jain GK 2006 Statins and osteoporosis: new role for old drugs. Journal of Pharmacy and Pharmacology 58 3-18.
26. Kano Y, Otsuka F, Takeda M, Suzuki J, Inagaki K, Miyoshi T, Miyamoto M, Otani H, Ogura T & Makino H 2005 Regulatory roles of bone morphogenetic proteins and glucocorticoids in catecholamine production by rat pheochromocytoma cells. Endocrinology 146 5332-5340.
27. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A & Suda T 1994 Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. Journal of Cell Biology 127 1755-1766.
28. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT Gao YH, Inada M et al. 1997 Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89 755-764.
29. Kudo O, Fujikawa Y, Itonaga I, Sabokbar A, Torisu T & Athanasou NA 2002 Proinflammatory cytokine (TNFalpha/IL- 1alpha) induction of human osteoclast formation. Journal of Pathology 198 220-227.
30. Liao JK & Laufs U 2005 Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 45 89-118.
31. Lieberman JR, Daluiski A & Einhorn TA 2002 The role of growth factors in the repair of bone. Biology and clinical applications. Journal of Bone and Joint Surgery, American Volume 84-A 1032-1044.
32. MacEwan DJ 2002 TNF receptor subtype signalling: differences and cellular consequences. Cellular Signalling 14 477-492.
33. Maeda T, Matsunuma A, Kawane T & Horiuchi N 2001 Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochemical and Biophysical Research Communications 280 874-877.
34. Maeda T, Kawane T & Horiuchi N 2003 Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 144 681-692.
35. Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H & Horiuchi N 2004 Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. Journal of Cellular Biochemistry 92 458-471.
36. Maron DJ, Fazio S & Linton MF 2000 Current perspectives on statins. Circulation 101 207-213.
37. McCarthy TL, Centrella M & Canalis E 1989 Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures. Endocrinology 124 301-309.
38. Midy V & Plouet J 1994 Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochemical and Biophysical Research Communications 199 380-386.
39. Miyoshi T, Otsuka F, Suzuki J, Takeda M, Inagaki K, Kano Y Otani H, Mimura Y, Ogura T & Makino H 2006 Mutual regulation of follicle-stimulating hormone signaling and bone morphogenetic protein system in human granulosa cells. Biology of Reproduction 74 1073-1082.
40. Mukai T, Otsuka F, Otani H, Yamashita M, Takasugi K, Inagaki K, Yamamura M & Makino H 2007 TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochemical and Biophysical Research Communications 356 1004-1010.
41. Mundy GR 1993 Cytokines and growth factors in the regulation of bone remodeling. Journal of Bone and Mineral Research 8 (Suppl 2) S505-S510.
42. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M & Gutierrez G 1999 Stimulation of bone formation in vitro and in rodents by statins. Science 286 1946-1949.
43. Noda M & Camilliere JJ 1989 In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology 124 2991-2994.
44. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y & Takayanagi R 2001 Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochemical and Biophysical Research Communications 287 337-342.
45. Otani H, Otsuka F, Inagaki K, Takeda M, Miyoshi T, Suzuki J, Mukai T, Ogura T & Makino H 2007 Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation. American Journal of Physiology, Renal Physiology 292 F1513-F1525.
46. Orsuka F & Shimasaki S 2002 A novel function of bone morphogenetic protein-15 in the pituitary: selective synthesis and secretion of FSH by gonadotropes. Endocrinology 143 4938-4941.
47. Otsuka F, Yao Z, Lee TH, Yamamoto S, Erickson GF & Shimasaki S 2000 Bone morphogenetic protein-15: identification of target cells and biological functions. Journal of Biological Chemistry 275 39523-39528.
48. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR et al. 1997 Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89 765-771.
49. Pammer J, Reinisch C, Kaun C, Tschachler E & Wojta J 2004 Inhibitors of differentiation/DNA binding proteins Id1 and Id3 are regulated by statins in endothelial cells. Endothelium 11 175-180.
50. Reddi AH 1997 Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine and Growth Factor Reviews 8 11-20.
51. Rosenson RS, Tangney CC & Casey LC 1999 Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353 983-984.
52. Scott DL & Kingsley GH 2006 Tumor necrosis factor inhibitors for rheumatoid arthritis. New England Journal of Medicine 355 704-712.
53. Shimasaki S, Moore RK, Otsuka F & Erickson GF 2004 The bone morphogenetic protein system in mammalian reproduction. Endocrine Reviews 25 72-101.
54. Shirai H, Autieri M & Eguchi S 2007 Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling. Current Opinion in Nephrology and Hypertension 16 111-115.
55. Spelsberg TC, Subramaniam M, Riggs BL & Kbosla S 1999 The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Molecular Endocrinology 13 819-828.
56. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S & Oikawa S 2000 Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochemical and Biophysical Research Communications 271 688-692.
57. Suzuki J, Otsuka F, Inagaki K, Takeda M, Ogura T & Makino H 2004 Novel action of activin and bone morphogenetic protein in regulating aldosterone production by human adrenocortical cells. Endocrinology 145 639-649.
58. Suzuki J, Otsuka F, Takeda M, Inagaki K, Miyoshi T, Mimura Y, Ogura T, Doihara H & Makino H 2005 Functional roles of the bone morphogenetic protein system in thyrotropin signaling in porcine thyroid cells. Biochemical and Biophysical Research Communications 327 1124-1130.
59. Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A & Suda T 1988 Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122 1373-1382.
60. Takasugi K, Yamamura M, Iwahashi M, Otsuka F, Yamana J, Sunahori K, Kawashima M, Yamada M & Makino H 2006 Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis. Arthritis Research and Therapy 8 R126.
61. Takeda M, Otsuka F, Nakamura K, Inagaki K, Suzuki J, Miura D, Fujio H, Matsubara H, Date H, Ohe T et al. 2004 Characterization of the bone morphogenetic protein (BMP) system in human pulmonary arterial smooth muscle cells isolated from a sporadic case of primary pulmonary hypertension: roles of BMP type IB receptor (activin receptor-like kinase-6) in the mitotic action. Endocrinology 145 4344-4354.
62. Wajant H, Pfizenmaier K & Scheurich P 2003 Tumor necrosis factor signaling. Cell Death and Differentiation 10 45-65.
63. Woo JT, Kasai S, Stern PH & Nagai K 2000 Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. Journal of Bone and Mineral Research 15 650-662.